Alpha Cognition INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Alpha Cognition Inc. commercially launched its Alzheimer's treatment ZUNVEYL, generating initial revenue, but reported a significant increase in net losses for the fiscal year ended December 31, 2025.
NASDAQ
Alpha Cognition Inc.'s annual report highlights FDA approval of ZUNVEYL for Alzheimer's and outlines commercialization plans targeting the long-term care market.